<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655614</url>
  </required_header>
  <id_info>
    <org_study_id>GN29823</org_study_id>
    <secondary_id>2017-002931-41</secondary_id>
    <nct_id>NCT02655614</nct_id>
  </id_info>
  <brief_title>A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in
      participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and
      pharmacokinetic (PK) properties of GDC-0134. It will include three components: a
      Single-Ascending-Dose (SAD) stage, a Multiple-Ascending-Dose (MAD) stage, and an Open-Label
      Safety Expansion (OSE) stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2016</start_date>
  <completion_date type="Anticipated">October 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From randomization up to approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>From randomization up to approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Vital Signs Abnormalities</measure>
    <time_frame>From randomization up to approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From randomization up to approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings</measure>
    <time_frame>From randomization up to approximately 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (tmax) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Cmax (Cmax/Dose) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized AUC (AUC/Dose) of GDC-0134</measure>
    <time_frame>From Day 1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Midazolam</measure>
    <time_frame>From Day -1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)</measure>
    <time_frame>From Day -1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Caffeine</measure>
    <time_frame>From Day -1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Paraxanthine (Metabolite of Caffeine)</measure>
    <time_frame>From Day -1 up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>SAD Stage: GDC-0134</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Stage: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Stage: GDC-0134</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Stage: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Safety Expansion (OSE)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0134</intervention_name>
    <description>GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.</description>
    <arm_group_label>SAD Stage: GDC-0134</arm_group_label>
    <arm_group_label>MAD Stage: GDC-0134</arm_group_label>
    <arm_group_label>Open-Label Safety Expansion (OSE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to GDC-0134</description>
    <arm_group_label>SAD Stage: Placebo</arm_group_label>
    <arm_group_label>MAD Stage: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Rabeprazole 20 mg twice daily orally</description>
    <arm_group_label>SAD Stage: GDC-0134</arm_group_label>
    <arm_group_label>SAD Stage: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2mg of liquid formulation of midazolam orally</description>
    <arm_group_label>MAD Stage: GDC-0134</arm_group_label>
    <arm_group_label>MAD Stage: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>100 mg tablet or solution of caffeine orally</description>
    <arm_group_label>MAD Stage: GDC-0134</arm_group_label>
    <arm_group_label>MAD Stage: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants with a diagnosis of possible, laboratory-supported
             probable, probable, or definite ALS according to modified El Escorial criteria

          -  Upright forced vital capacity of at least 50 percent (%)

          -  Ability to fast from food for 8 hours prior to dosing and 2 hours after dosing

        Exclusion Criteria:

          -  Currently taking riluzole unless on a stable dose for the 3 months prior to Day -1 and
             without current liver enzyme or liver function abnormalities

          -  Currently taking edaravone unless after completion of at least the second 14-day
             drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24
             hours after the last edaravone dose and at least 5 days prior to the first dose of the
             next cycle

          -  Positive for hepatitis C antibody, hepatitis B surface antigen, or human
             immunodeficiency virus (HIV) antibody

          -  Clinically significant thrombocytopenia

          -  Currently taking nutritional/herbal supplements, except for over-the-counter vitamins
             that are within Recommended Dietary Allowance (RDA), unless discontinued at least 7
             days prior to Day −1, except upon approval of both the investigator and Sponsor

          -  For participants participating in a designated drug-drug interaction (DDI) cohort in
             the MAD stage of the study, who require midazolam/caffeine administration: known
             allergy, religious prohibition, or other condition limiting midazolam or caffeine
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN29823 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Forbes Norris Mda/als Ctr; Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory ALS Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUCH - Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

